Recently, a new study sought to examine treatment patterns in US patients new to anti–tumor necrosis factor (anti-TNF) therapy, and it found that a majority of patients, particularly women, do not remain on their first anti-TNF after 2 years.
Ankylosing spondylitis (AS) may be treated with anti—tumor necrosis factor (anti-TNF) agents, but primary treatment failure, loss of response over time, or adverse events can prompt discontinuation. Previous research has also shown that women with AS have lower anti-TNF treatment retention than men with AS. Recently, a new study sought to examine treatment patterns in US patients new to anti-TNF therapy, and it found that a majority of patients, particularly women, do not remain on their first anti-TNF after 2 years.
The observational, retrospective, cross-sectional study was based on data from the IBM MarketScan Research database, which includes deidentified data for more than 50 million covered lives. Adults with AS who had at least 1 claim for an anti-TNF between 2009 and 2013 were included in the cohort.
In total, 1374 patients met the inclusion criteria; 61.7% were male, and the mean age was 43.8 years. Most patients (91.3%) had commercial insurance.
The patients started treatment with adalimumab (44.1%), etanercept (40.9%), infliximab (10.6%), golimumab (4.3%), and certolizumab pegol (0.1%). During the 2-year followup period, only 33.1% of patients were still using their first anti-TNF, whereas 40.7% had discontinued and did not start another anti-TNF and 26.1% switched to a second anti-TNF. Among those who switched, 20.1% went on to switch to a third anti-TNF.
In total, during the 2-year follow-up, 32.6% of men persisted on their first anti-TNF versus 22.8% of women.
Patients who were prescribed conventional disease-modifying antirheumatic drugs were more likely to be persistent on their first anti-TNF. Women and patients treated with opioids were less likely to be persistent on their first anti-TNF and were also more likely to switch to another.
The investigators note that, during the study period, interleukin-17 inhibitors were not available, so it is not possible to know whether switching to such options would have impacted the observed treatment patterns.
More research is needed, they write, to understand the reasons for nonpersistence and the increasing trend of second-line anti-TNF use among patients with AS.
Reference
Hunter T, Schroeder K, Sandoval D, Deodhar A. Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States [published online March 5, 2019]. Rheumatol Ther. doi: 10.1007/s40744-019-0148-4.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.